Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00360282
Status:
COMPLETED
Last Update Posted:
2014-12-08
First Post:
2006-08-02
Brief Title:
Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if Rizatriptan a migraine medication lowers motion sickness in migraine sufferers
Detailed Description:
Migraine sufferers undergo vestibular tests and were excluded if there were clinically significant abnormalities Following screening there were 2 experimental visits in which migraine sufferers were pre-treated with either Rizatriptan or placebo After taking the drug subjects were idle for 2 hours Baseline motion sickness and subjective units of distress levels were assessed prior to undergoing sinusoidal-earth-vertical earth axis rotation in darkness at 005 Hz Scores were taken immediately after stopping Subjects were given a 2 minutes rest and then underwent a motion sickness provoking rotation Subjective scores were assessed immediately following Another two minute rest was given and if the subject was able underwent a second motion sickness provoking stimulus followed by an assessment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 31449 | OTHER | Merck | None |